Sprint Bioscience is a pharmaceutical company based in Huddinge, Sweden, founded in 2009. The company specializes in the research and development of innovative cancer drugs, focusing on small-molecule, first-in-class drug candidates. Using a fragment-based drug discovery approach, Sprint Bioscience aims to create breakthrough treatments for difficult-to-treat cancers.

The company has a strong emphasis on preclinical drug development, particularly in oncology, while also exploring areas like tumor metabolism, diabetes, and non-alcoholic steatohepatitis. Its drug pipeline includes candidates for solid tumors, leukemia, melanoma, and other neoplasms. Notable programs include the NIMA project, which targets the tumor microenvironment to inhibit cancer growth and enhance immune response.

Sprint Bioscience employs around 35 people, fostering collaboration across scientific disciplines to drive successful project execution. The company out-licenses its preclinical drug candidates to global pharmaceutical companies, leveraging partnerships to efficiently bring innovative cancer treatments to market.